

# Rosario LÃ³pez-RodrÃ­guez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4651904/publications.pdf>

Version: 2024-02-01

41  
papers

981  
citations

471061

17  
h-index

476904

29  
g-index

45  
all docs

45  
docs citations

45  
times ranked

1608  
citing authors

#	ARTICLE	IF	CITATIONS
1	SARS-CoV-2 Point Mutation and Deletion Spectra and Their Association with Different Disease Outcomes. <i>Microbiology Spectrum</i> , 2022, 10, e0022122.	1.2	10
2	Novel genes and sex differences in COVID-19 severity. <i>Human Molecular Genetics</i> , 2022, 31, 3789-3806.	1.4	38
3	SARS-CoV-2 Mutant Spectra at Different Depth Levels Reveal an Overwhelming Abundance of Low Frequency Mutations. <i>Pathogens</i> , 2022, 11, 662.	1.2	16
4	Genetic landscape of 6089 inherited retinal dystrophies affected cases in Spain and their therapeutic and extended epidemiological implications. <i>Scientific Reports</i> , 2021, 11, 1526.	1.6	71
5	IL-6â€“based mortality prediction model for COVID-19: Validation and update in multicenter and second wave cohorts. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 1652-1661.e1.	1.5	14
6	NGS and phenotypic ontology-based approaches increase the diagnostic yield in syndromic retinal diseases. <i>Human Genetics</i> , 2021, 140, 1665-1678.	1.8	9
7	High SARS-CoV-2 viral load is associated with a worse clinical outcome of COVID-19 disease. <i>Access Microbiology</i> , 2021, 3, 000259.	0.2	13
8	RPE65-related retinal dystrophy: Mutational and phenotypic spectrum in 45 affected patients. <i>Experimental Eye Research</i> , 2021, 212, 108761.	1.2	11
9	Evaluation of a clinical pharmacogenetics model to predict methotrexate response in patients with rheumatoid arthritis. <i>Pharmacogenomics Journal</i> , 2018, 18, 539-545.	0.9	14
10	Effect of ABCB1 C3435T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 123, 474-485.	1.2	51
11	Effect of Polymorphisms on the Pharmacokinetics, Pharmacodynamics and Safety of Sertraline in Healthy Volunteers. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 122, 501-511.	1.2	45
12	Validation study of genetic biomarkers of response to TNF inhibitors in rheumatoid arthritis. <i>PLoS ONE</i> , 2018, 13, e0196793.	1.1	13
13	Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis. <i>Scientific Reports</i> , 2018, 8, 7342.	1.6	18
14	Intrahepatic angiotensinâ€“2 correlates with chronic hepatitis C progression and is induced in hepatitis C virus replicon systems. <i>Liver International</i> , 2017, 37, 1148-1156.	1.9	4
15	Interferon-related genetic markers of necroinflammatory activity in chronic hepatitis C. <i>PLoS ONE</i> , 2017, 12, e0180927.	1.1	8
16	Independent Candidate Serum Protein Biomarkers of Response to Adalimumab and to Infliximab in Rheumatoid Arthritis: An Exploratory Study. <i>PLoS ONE</i> , 2016, 11, e0153140.	1.1	19
17	Angiotensin-2/angiotensin-1 as non-invasive biomarker of cirrhosis in chronic hepatitis C. <i>World Journal of Gastroenterology</i> , 2016, 22, 9744.	1.4	16
18	Pharmacogenetics of quetiapine in healthy volunteers. <i>International Clinical Psychopharmacology</i> , 2015, 30, 82-88.	0.9	23

#	ARTICLE	IF	CITATIONS
19	High-Resolution Hepatitis C Virus Subtyping Using NS5B Deep Sequencing and Phylogeny, an Alternative to Current Methods. <i>Journal of Clinical Microbiology</i> , 2015, 53, 219-226.	1.8	74
20	Polymorphisms in <i>CYP2D6</i> have a Greater Effect on Variability of Risperidone Pharmacokinetics than Gender. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2015, 116, 124-128.	1.2	17
21	Inhibition of Tyrosine Kinase Receptor Tie2 Reverts HCV-Induced Hepatic Stellate Cell Activation. <i>PLoS ONE</i> , 2014, 9, e106958.	1.1	6
22	Effect of polymorphisms on the pharmacokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers. <i>Human Psychopharmacology</i> , 2014, 29, 459-469.	0.7	33
23	Diversity of Killer Cell Immunoglobulin-Like Receptor (KIR) Genotypes and KIR2DL2/3 Variants in HCV Treatment Outcome. <i>PLoS ONE</i> , 2014, 9, e99426.	1.1	12
24	Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers. <i>Pharmacogenomics</i> , 2013, 14, 1203-1214.	0.6	9
25	Preliminary evidence of sustained expression of angiotensinâ€² during monocyte differentiation in chronic hepatitis C. <i>Liver International</i> , 2013, 33, 864-870.	1.9	3
26	Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects. <i>Human Psychopharmacology</i> , 2013, 28, 205-214.	0.7	43
27	Evaluation of the Relationship between Sex, Polymorphisms in <i>CYP2C8</i> and <i>CYP2C9</i> , and Pharmacokinetics of Angiotensin Receptor Blockers. <i>Drug Metabolism and Disposition</i> , 2013, 41, 224-229.	1.7	45
28	Polymorphisms in histone deacetylases improve the predictive value of IL-28B for chronic hepatitis C therapy. <i>Genes and Immunity</i> , 2013, 14, 317-324.	2.2	10
29	Angiotensin-2 Serum Levels Improve Noninvasive Fibrosis Staging in Chronic Hepatitis C: A Fibrogenic-Angiogenic Link. <i>PLoS ONE</i> , 2013, 8, e66143.	1.1	13
30	A predictive model of treatment outcome in patients with chronic HCV infection using IL28B and PD-1 genotyping. <i>Journal of Hepatology</i> , 2012, 56, 1230-1238.	1.8	19
31	Genetic Variants of Interferon-Stimulated Genes and IL-28B as Host Prognostic Factors of Response to Combination Treatment for Chronic Hepatitis C. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 90, 712-721.	2.3	18
32	DRD2 Taq1A Polymorphism Modulates Prolactin Secretion Induced by Atypical Antipsychotics in Healthy Volunteers. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 555-562.	0.7	32
33	Peripheral blood monocyte subsets predict antiviral response in chronic hepatitis C. <i>Alimentary Pharmacology and Therapeutics</i> , 2011, 34, 960-971.	1.9	24
34	ATA homozygosity in the IL-10 gene promoter is a risk factor for schizophrenia in Spanish females: a case control study. <i>BMC Medical Genetics</i> , 2011, 12, 81.	2.1	15
35	Allele and Genotype Frequencies of Serotonin and Dopamine Transporter and Receptor Polymorphisms in a Norwegian Population. <i>Genetic Testing and Molecular Biomarkers</i> , 2011, 15, 557-563.	0.3	2
36	Effects of CYP2D6 Genotype on the Pharmacokinetics, Pharmacodynamics, and Safety of Risperidone in Healthy Volunteers. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 504-511.	0.7	57

#	ARTICLE	IF	CITATIONS
37	Evaluating a newly developed pharmacogenetic array: screening in a Spanish population. <i>Pharmacogenomics</i> , 2010, 11, 1619-1625.	0.6	12
38	Pharmacogenetic relevance of the CYP2C93 allele in a tenoxicam bioequivalence study performed on Spaniards. <i>Pharmacological Research</i> , 2009, 59, 62-68.	3.1	13
39	Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers. <i>Pharmacological Research</i> , 2009, 59, 393-398.	3.1	27
40	Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers. <i>Pharmacological Research</i> , 2008, 58, 77-84.	3.1	59
41	Lithium and venlafaxine interaction: a case of serotonin syndrome. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2006, 31, 397-400.	0.7	37